Protein may predict chemotherapy response in osteosarcoma

Share this article:

The expression of the P16 protein, which inhibits cell growth, may be a useful biomarker for predicting how osteosarcoma will respond to standard chemotherapy, researchers concluded after finding that P16 expression significantly correlates with chemotherapy response among patients with that form of cancer.

As a team led by Dariusz Borys of the University of California–Davis Department of Pathology and Laboratory Medicine in Sacramento explained in Human Pathology, pathologic response to neoadjuvant chemotherapy is highly correlated with survival among persons with osteosarcoma, the most common bone cancer in children. (Osteosarcoma can also affect people after age 60 years.) However, there are no established molecular markers to predict response to this treatment.

The research group analyzed data from pretreatment biopsy specimens of 40 patients with osteosarcoma. The median age of the patients was 15 years (range, 9 to 75 years), and 35% of the biopsied tumors were located in the femur. P16 expression was found to be present in 62% of the specimens.

Following chemotherapy, during surgery to remove the tumor, specimens were again collected and analyzed. Median tumor necrosis was 90%, and 55% of patients experienced “good” chemotherapy response, defined as tumor necrosis of at least 90%. These patients were significantly more likely to have had tumors that expressed the P16 protein.

After the researchers controlled for patient age and gender and for tumor subtype and location, P16 expression was independently associated with chemotherapy response.

.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Early promise against melanoma from new antibody-drug conjugate

The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.

Aging is sped up in breast cancer survivors who underwent adjuvant chemotherapy

Adjuvant chemotherapy for breast cancer is gerontogenic, defined as accelerating the pace of physiologic aging, a new study reported.

Subset of patients with breast cancer patients will most likely benefit from ...

The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.